DalsnaFinance › Analyst accuracy › Stifel › DYN target
Stifel reiterates Dyne Therapeutics stock rating on trial data
Stifel reiterated a Buy rating and $37.00 price target on Dyne Therapeutics (NASDAQ:DYN) following new trial data presentations.
A fact about what Stifel published, as reported by Investing.com, not a recommendation from Dalsna Finance; Stifel is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.